Phase 2 Stomach Cancer Trial, Recruiting NCT05640830 Sponsor: Kangbuk Samsung Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT05640830
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have advanced gastric (stomach) cancer that tests positive for a protein called HER2, confirmed through specific laboratory tests (including tissue staining tests or gene copy number tests), or through a specialised protein analysis method.
  • People whose stomach cancer has continued to grow or spread after receiving one round of systemic cancer treatment (such as chemotherapy).
  • People who are willing and able to sign a written consent form to take part in the trial.
  • People who are aged 19 years or older at the time of signing the consent form.
  • People who have at least one area of cancer that can be measured or assessed on scans, according to standard medical guidelines (RECIST 1.1).
  • People who are reasonably active and able to carry out daily activities, as measured by a standard medical scale (ECOG score of 0, 1, or 2).
  • People whose blood, kidney, liver, and heart function meet specific minimum levels on tests taken within 2 weeks before starting treatment (confirm specific values with trial site).

Who may not be able to join:

  • People who have received chemotherapy, radiation, immunotherapy, or targeted therapy for stomach cancer within the past 2 weeks.
  • People who have had a severe (Grade 3–4) gastrointestinal bleed within the past 3 months.
  • People who have had a serious blood vessel or heart event — such as a heart attack, mini-stroke, stroke, or unstable chest pain — within the past 6 months.
  • People who currently have an active infection, uncontrolled heart failure, unstable chest pain, poorly controlled heart rhythm problems, or uncontrolled blood clotting or bleeding disorders, or any other serious uncontrolled medical condition.
  • People who have had a hole (perforation) or abnormal channel (fistula) in their gastrointestinal tract within the past 6 months.
  • People who currently have cancer in another part of the body, or who have had another active cancer within the past 3 years — though people with a history of certain fully treated cancers (such as basal cell skin cancer, thyroid cancer, or cervical cancer in situ) may still be considered (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dong-Hoe Koo, MD,PhD, Kangbuk Samsung Hospital

Phone: +82-2-2001-8330

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Kangbuk Samsung Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov